세계의 분자진단 자동화 시장 : 유형, 자동화 유형, 제품, 용도, 최종 용도별 예측(2025-2030년)

The Automation in the Molecular Diagnostics Market was valued at USD 11.75 billion in 2023, expected to reach USD 13.54 billion in 2024, and is projected to grow at a CAGR of 15.79%, to USD 32.81 billion by 2030.

Automation in molecular diagnostics refers to the integration of advanced technologies and automated systems to streamline and enhance the processes involved in the detection and analysis of molecules for various medical and research purposes. The necessity for automation in this field is driven by the need for higher precision, reduced errors, faster processing time, and increased throughput, which are crucial for responding effectively to the growing demand for diagnostic tests. Applications of automation span across sample preparation, assay development, data analysis, and result interpretation, significantly benefiting laboratories, hospitals, and research institutions. The end-use scope is expansive, catering to clinical diagnostics, drug discovery, personalized medicine, and epidemiology.

Market insights reveal that key growth factors include the rising prevalence of chronic diseases, increased demand for personalized medicine, and technological advancements in diagnostic equipment. Furthermore, emerging opportunities are presented by the integration of artificial intelligence and machine learning, which promise to revolutionize data interpretation and operational efficiency in diagnostic processes. Companies can capture these opportunities by investing in Research & Development for AI-driven platforms and by forming strategic partnerships to enhance expertise and market reach.

However, the market faces limitations such as high cost of implementation, regulatory hurdles, and ethical concerns surrounding data privacy and management. Addressing these challenges requires developing cost-effective solutions and robust cybersecurity measures, as well as a clear regulatory framework to ensure compliance.

Innovation areas ripe for exploration include the development of point-of-care testing solutions, improved biosensors, and lab-on-a-chip technologies that promise to decentralize and expedite diagnostic services. Research in nanotechnology and bioinformatics can also provide avenues for breakthrough improvements in sensitivity and specificity of diagnostic tests. The nature of this market is dynamic and competitive, necessitating constant vigilance and adaptability to new trends and technologies to sustain growth and relevance in the field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Automation in the Molecular Diagnostics Market

The Automation in the Molecular Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of chronic diseases across the globe
  • Need for accuracy and speed in molecular diagnostics
  • Rising focus on personalized healthcare and precision medicine
• Market Restraints
  • High initial investment associated with automation technology
• Market Opportunities
  • Rising collaborative activities among technology providers and molecular diagnostics companies
  • Government programs and funding in healthcare infrastructure and research
• Market Challenges
  • Stringent regulations associated with the approval process

Porter's Five Forces: A Strategic Tool for Navigating the Automation in the Molecular Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Automation in the Molecular Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Automation in the Molecular Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Automation in the Molecular Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Automation in the Molecular Diagnostics Market

A detailed market share analysis in the Automation in the Molecular Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Automation in the Molecular Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Automation in the Molecular Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Automation in the Molecular Diagnostics Market

A strategic analysis of the Automation in the Molecular Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Automation in the Molecular Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaltis S.r.l., Agilent Technologies, Inc., altona Diagnostics GmbH, Aurora Biomed Inc., Becton, Dickinson and Company, Biocartis NV, bioMerieux SA, Bruker Corporation, Danaher Corporation, DiaSorin S.p.A., Eppendorf SE, F. Hoffmann-La Roche Ltd., Festo Corporation, Hamilton Company, Hologic, Inc., Hudson Robotics, Inc., LabVantage Solutions Inc., MEGAROBO technologies Co., Ltd., Meridian Bioscience, Inc., Molgen B.V., Mylab Discovery Solutions Pvt. Ltd., QIAGEN N.V., QuidelOrtho Corporation, Revvity, Inc., Sansure Biotech Inc., Scispot.io Inc., Seegene Inc., Siemens Healthineers AG, Sysmex Corporation, Tecan Group Ltd., Thermo Fisher Scientific Inc., Vela Diagnostics Holding Pte Ltd., and Waters Corporation.

Market Segmentation & Coverage

This research report categorizes the Automation in the Molecular Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Amplification Automation, Analysis Automation, Extraction Automation, Post-analytical Automation, and Pre-analytical Automation.
• Based on Automation Type, market is studied across Modular Automation and Total Lab Automation.
• Based on Product, market is studied across Equipment, Services, and Software.
• Based on Application, market is studied across Blood Screening, Genetic Testing, Infectious Diseases, and Oncology.
• Based on End-use, market is studied across Clinical Laboratories, Hospitals, and Research Institutions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of chronic diseases across the globe
    • 5.1.1.2. Need for accuracy and speed in molecular diagnostics
    • 5.1.1.3. Rising focus on personalized healthcare and precision medicine
  • 5.1.2. Restraints
    • 5.1.2.1. High initial investment associated with automation technology
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising collaborative activities among technology providers and molecular diagnostics companies
    • 5.1.3.2. Government programs and funding in healthcare infrastructure and research
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations associated with the approval process
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Increasing significance of amplification automation in high-throughput settings
  • 5.2.2. Automation Type: Enhancing efficiency in molecular diagnostics with total lab automation and modular solutions
  • 5.2.3. Product: Revolutionizing and integrating the automation into the software and equipment of molecular diagnostics
  • 5.2.4. Application: Automation enhances precision in cancer, infectious disease, genetic testing, and blood screening
  • 5.2.5. End-use: Research institutions prefer highly customizable and scalable automation solutions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Automation in the Molecular Diagnostics Market, by Type

• 6.1. Introduction
• 6.2. Amplification Automation
• 6.3. Analysis Automation
• 6.4. Extraction Automation
• 6.5. Post-analytical Automation
• 6.6. Pre-analytical Automation

7. Automation in the Molecular Diagnostics Market, by Automation Type

• 7.1. Introduction
• 7.2. Modular Automation
• 7.3. Total Lab Automation

8. Automation in the Molecular Diagnostics Market, by Product

• 8.1. Introduction
• 8.2. Equipment
• 8.3. Services
• 8.4. Software

9. Automation in the Molecular Diagnostics Market, by Application

• 9.1. Introduction
• 9.2. Blood Screening
• 9.3. Genetic Testing
• 9.4. Infectious Diseases
• 9.5. Oncology

10. Automation in the Molecular Diagnostics Market, by End-use

• 10.1. Introduction
• 10.2. Clinical Laboratories
• 10.3. Hospitals
• 10.4. Research Institutions

11. Americas Automation in the Molecular Diagnostics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Automation in the Molecular Diagnostics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Automation in the Molecular Diagnostics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Biocare Medical and Molecular Instruments Join Forces to Elevate Bioimaging Technologies
  • 14.3.2. Roche Diagnostics and Hitachi High-Tech Extend 46-Year Partnership to Innovate Molecular Diagnostic Automation
  • 14.3.3. Bruker Corporation Acquires ELITechGroup for EUR 870 million to Boost Diagnostic Capabilities
  • 14.3.4. Devyser Diagnostics and Hamilton Partner to Automate and Enhance Genetic Testing Workflows
  • 14.3.5. Bosch Healthcare and Randox Invest USD 159 Million to Advance Vivalytic Molecular Diagnostics Platform
  • 14.3.6. HORIBA Medical Unveils HELO 2.0, Advancing Automated Hematology with CE-IVDR Approval and Awaiting FDA Nod
  • 14.3.7. The Launch of BugCount Guardian by LuminUltra to Enhnace Industrial Microbial Monitoring
  • 14.3.8. Yourgene Health Unveils Revolutionary MagBench Technology for Enhanced Non-Invasive Prenatal Testing
  • 14.3.9. Menarini Diagnostics Launches PRIME MDx Platform, Revolutionizing Automated Molecular Diagnostics
  • 14.3.10. Mylab Discovery Solutions and AstraGene LLC Form Partnership to Advance Automated Molecular Diagnostics in UAE and Kuwait
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. F. Hoffmann-La Roche Ltd.
  • 14.4.2. Meridian Bioscience, Inc.
  • 14.4.3. Revvity, Inc.
  • 14.4.4. Seegene Inc.

Companies Mentioned

• 1. Abbott Laboratories
• 2. Adaltis S.r.l.
• 3. Agilent Technologies, Inc.
• 4. altona Diagnostics GmbH
• 5. Aurora Biomed Inc.
• 6. Becton, Dickinson and Company
• 7. Biocartis NV
• 8. bioMerieux SA
• 9. Bruker Corporation
• 10. Danaher Corporation
• 11. DiaSorin S.p.A.
• 12. Eppendorf SE
• 13. F. Hoffmann-La Roche Ltd.
• 14. Festo Corporation
• 15. Hamilton Company
• 16. Hologic, Inc.
• 17. Hudson Robotics, Inc.
• 18. LabVantage Solutions Inc.
• 19. MEGAROBO technologies Co., Ltd.
• 20. Meridian Bioscience, Inc.
• 21. Molgen B.V.
• 22. Mylab Discovery Solutions Pvt. Ltd.
• 23. QIAGEN N.V.
• 24. QuidelOrtho Corporation
• 25. Revvity, Inc.
• 26. Sansure Biotech Inc.
• 27. Scispot.io Inc.
• 28. Seegene Inc.
• 29. Siemens Healthineers AG
• 30. Sysmex Corporation
• 31. Tecan Group Ltd.
• 32. Thermo Fisher Scientific Inc.
• 33. Vela Diagnostics Holding Pte Ltd.
• 34. Waters Corporation